{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:18:30Z","timestamp":1791389910903,"version":"4.3.3"},"reference-count":148,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ajog.2025.09.002","type":"journal-article","created":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T23:45:01Z","timestamp":1757375101000},"page":"7-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Hydroxychloroquine in systemic lupus erythematosus, anti-SSA\/SSB, and antiphospholipid antibody-positive pregnancies"],"prefix":"10.1016","volume":"234","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-9474-8516","authenticated-orcid":false,"given":"Zeinab F.","family":"Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Somers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian C.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Marder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2025.09.002_bib1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/acr.25279","article-title":"Pregnancy outcomes in a diverse US lupus cohort","volume":"76","author":"Simard","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ajog.2025.09.002_bib2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.7326\/M19-0120","article-title":"Trends in maternal and fetal outcomes among pregnant women with systemic lupus erythematosus in the United States: a cross-sectional analysis","volume":"171","author":"Mehta","year":"2019","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajog.2025.09.002_bib3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/annrheumdis-2017-211641","article-title":"Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study","volume":"77","author":"Skorpen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajog.2025.09.002_bib4","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s10067-016-3270-5","article-title":"Organ-specific systemic lupus erythematosus activity during pregnancy is associated with adverse pregnancy outcomes","volume":"35","author":"Tedeschi","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib5","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/rheumatology\/39.9.1014","article-title":"Outcome of lupus pregnancy: a controlled study","volume":"39","author":"Georgiou","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ajog.2025.09.002_bib6","first-page":"16","article-title":"Reproductive health in systemic lupus erythematosus, an experience from government hospital in Western India","volume":"64","author":"Kothari","year":"2016","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.ajog.2025.09.002_bib7","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000651","article-title":"Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data","volume":"9","author":"Clowse","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ajog.2025.09.002_bib8","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","article-title":"Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology","volume":"16","author":"Schrezenmeier","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib9","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1002\/art.22157","article-title":"Antimalarial agents: closing the gate on Toll-like receptors?","volume":"54","author":"Lafyatis","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajog.2025.09.002_bib10","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0192-0561(87)90027-0","article-title":"Effect of antimalarial drugs on stimulation and interleukin 2 production of human lymphocytes","volume":"9","author":"Bygbjerg","year":"1987","journal-title":"Int J Immunopharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.ajog.2025.09.002_bib11","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1177\/0961203393002001031","article-title":"Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation","volume":"2","author":"Fox","year":"1993","journal-title":"Lupus"},{"key":"10.1016\/j.ajog.2025.09.002_bib12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0002-9343(83)91266-4","article-title":"Immunosuppressive potential of antimalarials","volume":"75","author":"Salmeron","year":"1983","journal-title":"Am J Med"},{"key":"10.1016\/j.ajog.2025.09.002_bib13","first-page":"55","article-title":"Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells","volume":"24","author":"van den Borne","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib14","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.4049\/jimmunol.165.3.1534","article-title":"Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism","volume":"165","author":"Weber","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/j.ajog.2025.09.002_bib15","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1177\/0961203312437270","article-title":"Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort","volume":"21","author":"Willis","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.ajog.2025.09.002_bib16","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s11427-020-1732-2","article-title":"Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19","volume":"63","author":"Yu","year":"2020","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.ajog.2025.09.002_bib17","doi-asserted-by":"crossref","first-page":"766","DOI":"10.6061\/clinics\/2013(06)07","article-title":"Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients","volume":"68","author":"Silva","year":"2013","journal-title":"Clinics (Sao Paulo)"},{"issue":"4 Suppl","key":"10.1016\/j.ajog.2025.09.002_bib18","doi-asserted-by":"crossref","first-page":"S9.e1","DOI":"10.1016\/j.ajog.2015.08.003","article-title":"Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity","volume":"213","author":"Redman","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2025.09.002_bib19","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1136\/annrheumdis-2016-210012","article-title":"Hydroxychloroquine inhibits proinflammatory signalling pathways by targeting endosomal NADPH oxidase","volume":"76","author":"M\u00fcller-Calleja","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajog.2025.09.002_bib20","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1182\/blood.V95.11.3460","article-title":"Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties","volume":"95","author":"Goldman","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ajog.2025.09.002_bib21","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/annrheumdis-2012-eular.3169","article-title":"SAT0222 hydroxychloroquine reduces thrombosis (both arterial and venous) in systemic lupus erythematosus, particularly in antiphospholipid positive patients","volume":"71","author":"Law","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajog.2025.09.002_bib22","first-page":"S297","article-title":"Arterial thrombotic events (TE) in SLE: the Baltimore Lupus Cohort study","volume":"37","author":"Petri","year":"1994","journal-title":"Arthr. Rheum"},{"key":"10.1016\/j.ajog.2025.09.002_bib23","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0961203306071872","article-title":"Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus","volume":"15","author":"Ruiz-Irastorza","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.ajog.2025.09.002_bib24","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.1780301219","article-title":"Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus?","volume":"30","author":"Wallace","year":"1987","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajog.2025.09.002_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/art.24232","article-title":"Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies","volume":"61","author":"Tektonidou","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajog.2025.09.002_bib26","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/art.27289","article-title":"The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus","volume":"62","author":"Jung","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajog.2025.09.002_bib27","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1093\/rheumatology\/41.8.924","article-title":"A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome","volume":"41","author":"Erkan","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ajog.2025.09.002_bib28","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/09612033221074192","article-title":"Efficacy of hydroxychloroquine in the prevention of thromboembolic events: a systematic review and meta-analysis","volume":"31","author":"Barros Edington","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.ajog.2025.09.002_bib29","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/ard.2008.093013","article-title":"Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort","volume":"68","author":"Kaiser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajog.2025.09.002_bib30","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/art.41621","article-title":"Association of higher hydroxychloroquine blood levels with reduced thrombosis risk in systemic lupus erythematosus","volume":"73","author":"Petri","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib31","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1001\/jama.1960.03020150054010","article-title":"Use of antimalarial drugs as \"desludging\" agents in vascular disease processes","volume":"172","author":"MADOW","year":"1960","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ajog.2025.09.002_bib32","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3109\/03009746209165073","article-title":"Desludging action of hydroxychloroquine in R.A","volume":"8","author":"Cecchi","year":"1962","journal-title":"Acta Rheum Scand"},{"key":"10.1016\/j.ajog.2025.09.002_bib33","first-page":"48","article-title":"Modification of transoperative changes in blood fluidity by hydroxychloroquine: a possible explanation for the drug's antithrombotic effect","volume":"4","author":"Ernst","year":"1984","journal-title":"Pharmatherapeutica"},{"key":"10.1016\/j.ajog.2025.09.002_bib34","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0049-3848(94)90270-4","article-title":"On the inhibitory effect of chloroquine on blood platelet aggregation","volume":"74","author":"Jancinov\u00e1","year":"1994","journal-title":"Thromb Res"},{"key":"10.1016\/j.ajog.2025.09.002_bib35","first-page":"143","article-title":"[Antiaggregation action of chloroquine]","volume":"50","author":"Bertrand","year":"1990","journal-title":"Med Trop (Mars)"},{"key":"10.1016\/j.ajog.2025.09.002_bib36","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/0049-3848(95)00028-3","article-title":"Chloroquine inhibits stimulated platelets at the arachidonic acid pathway","volume":"77","author":"Nos\u00e1l","year":"1995","journal-title":"Thromb Res"},{"key":"10.1016\/j.ajog.2025.09.002_bib37","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1055\/s-0037-1613033","article-title":"Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies","volume":"87","author":"Espinola","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ajog.2025.09.002_bib38","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood-2008-03-144204","article-title":"Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers","volume":"112","author":"Rand","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ajog.2025.09.002_bib39","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3899\/jrheum.120157","article-title":"Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and\/or lupus anticoagulant in systemic lupus erythematosus","volume":"40","author":"Broder","year":"2013","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s12026-016-8812-z","article-title":"Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome","volume":"65","author":"Nuri","year":"2017","journal-title":"Immunol Res"},{"key":"10.1016\/j.ajog.2025.09.002_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102665","article-title":"A cell-based model to study mechanisms of endothelial-dependent thrombin generation in response to inflammation and its modulation by hydroxychloroquine","volume":"9","author":"Arachchillage","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.ajog.2025.09.002_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0271560","article-title":"Hydroxychloroquine reduces soluble Flt-1 secretion from human cytotrophoblast, but does not mitigate markers of endothelial dysfunction in vitro","volume":"17","author":"Kadife","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ajog.2025.09.002_bib43","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.placenta.2025.06.013","article-title":"Effect of hydroxychloroquine on trophoblastic invasion in relation to autophagy mediated by ET-1 and ERK","volume":"168","author":"Sung","year":"2025","journal-title":"Placenta"},{"key":"10.1016\/j.ajog.2025.09.002_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2025.151994","article-title":"Hydroxychloroquine confers placental protection in antiphospholipid syndrome: mechanistic insights into autophagy regulation and trophoblast dysfunction","volume":"770","author":"Qi","year":"2025","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ajog.2025.09.002_bib45","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1097\/HJH.0000000000003279","article-title":"Hydroxychloroquine reduces hypertension and soluble fms-like kinase-1 in a N\u03c9-nitro-l-arginine methyl ester-induced preeclampsia rat model","volume":"40","author":"Choi","year":"2022","journal-title":"J Hypertens"},{"key":"10.1016\/j.ajog.2025.09.002_bib46","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.reprotox.2019.05.056","article-title":"Effects of hydroxychloroquine on the human placenta-Findings from in vitro experimental data and a systematic review","volume":"87","author":"Scott","year":"2019","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.ajog.2025.09.002_bib47","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/art.10150","article-title":"Evidence of transplacental passage of hydroxychloroquine in humans","volume":"46","author":"Costedoat-Chalumeau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajog.2025.09.002_bib48","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S0022-3565(25)26585-5","article-title":"Effects of hydroxychloroquine on the growth of mammalian cells in vitro","volume":"141","author":"Gabourel","year":"1963","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ajog.2025.09.002_bib49","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard.32.6.547","article-title":"Action of chloroquine phosphate in rheumatoid arthritis. II. Chromosome damaging effect","volume":"32","author":"Neill","year":"1973","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajog.2025.09.002_bib50","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/acr.24130","article-title":"2020 American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ajog.2025.09.002_bib51","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","article-title":"British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids","volume":"62","author":"Russell","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ajog.2025.09.002_bib52","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.ard.2025.02.023","article-title":"EULAR recommendations for use of antirheumatic drugs in reproduction, pregnancy, and lactation: 2024 update","volume":"84","author":"R\u00fcegg","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajog.2025.09.002_bib53","doi-asserted-by":"crossref","first-page":"B41","DOI":"10.1016\/j.ajog.2022.09.001","article-title":"Society for maternal-fetal medicine consult series #64: systemic lupus erythematosus in pregnancy","volume":"228","author":"Silver","year":"2023","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2025.09.002_bib54","doi-asserted-by":"crossref","first-page":"e287","DOI":"10.1097\/AOG.0000000000003176","article-title":"ACOG Committee Opinion No. 776: immune modulating therapies in pregnancy and lactation","volume":"133","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2025.09.002_bib55","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/rheumatology\/keae168","article-title":"Hydroxychloroquine in lupus or rheumatoid arthritis pregnancy and risk of major congenital malformations: a population-based cohort study","volume":"64","author":"Nguyen","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ajog.2025.09.002_bib56","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/rheumatology\/keac372","article-title":"Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine","volume":"62","author":"Reynolds","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ajog.2025.09.002_bib57","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.42015","article-title":"Birth outcomes in women who have taken hydroxycholoroquine during pregnancy: a prospective cohort study","volume":"74","author":"Chambers","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib58","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1002\/bdr2.1943","article-title":"Maternal exposure to hydroxychloroquine and birth defects","volume":"113","author":"Howley","year":"2021","journal-title":"Birth Defects Res"},{"key":"10.1016\/j.ajog.2025.09.002_bib59","doi-asserted-by":"crossref","first-page":"290.e1","DOI":"10.1016\/j.ajog.2020.09.007","article-title":"Hydroxychloroquine early in pregnancy and risk of birth defects","volume":"224","author":"Huybrechts","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2025.09.002_bib60","first-page":"1080","article-title":"Perinatal exposure to conventional synthetic disease-modifying anti-rheumatic drugs in women with rheumatic disease and neonatal outcomes: a population-based study","volume":"38","author":"Howren","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib61","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/2810202","article-title":"Hydroxychloroquine use in lupus patients during pregnancy is associated with longer pregnancy duration in preterm births","volume":"2017","author":"Kroese","year":"2017","journal-title":"J Immunol Res"},{"key":"10.1016\/j.ajog.2025.09.002_bib62","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1177\/0961203315591027","article-title":"Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study","volume":"24","author":"Leroux","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.ajog.2025.09.002_bib63","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/art.38262","article-title":"Brief report: risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy","volume":"66","author":"Cooper","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib64","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.reprotox.2013.04.005","article-title":"Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study","volume":"39","author":"Diav-Citrin","year":"2013","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.ajog.2025.09.002_bib65","doi-asserted-by":"crossref","first-page":"196","DOI":"10.3109\/03009742.2011.626442","article-title":"Outcomes after anti-rheumatic drug use before and during pregnancy: a cohort study among 150,000 pregnant women and expectant fathers","volume":"41","author":"Viktil","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib66","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1002\/art.22159","article-title":"Hydroxychloroquine in lupus pregnancy","volume":"54","author":"Clowse","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajog.2025.09.002_bib67","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1002\/art.11304","article-title":"Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group","volume":"48","author":"Costedoat-Chalumeau","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajog.2025.09.002_bib68","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1191\/096120301678646137","article-title":"Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study","volume":"10","author":"Levy","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.ajog.2025.09.002_bib69","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/ard.55.7.486","article-title":"Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases","volume":"55","author":"Buchanan","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajog.2025.09.002_bib70","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1093\/rheumatology\/keaa592","article-title":"Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study","volume":"60","author":"Andersson","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ajog.2025.09.002_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.722511","article-title":"Chloroquine and hydroxychloroquine use during pregnancy and the risk of adverse pregnancy outcomes using real-world evidence","volume":"12","author":"B\u00e9rard","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ajog.2025.09.002_bib72","doi-asserted-by":"crossref","first-page":"e501","DOI":"10.1016\/S2665-9913(23)00215-1","article-title":"Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases","volume":"5","author":"Schreiber","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib73","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/j.gastro.2020.05.001","article-title":"AGA institute rapid review of the gastrointestinal and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19","volume":"159","author":"Sultan","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ajog.2025.09.002_bib74","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.55563\/clinexprheumatol\/styx9u","article-title":"The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events","volume":"39","author":"Gisondi","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib75","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1080\/15563650.2020.1817479","article-title":"Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose","volume":"59","author":"Doyno","year":"2021","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.ajog.2025.09.002_bib76","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1177\/10600280221113572","article-title":"Systematic review of psychiatric adverse effects induced by chloroquine and hydroxychloroquine: case reports and population studies","volume":"57","author":"Talarico","year":"2023","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ajog.2025.09.002_bib77","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.ophtha.2016.01.058","article-title":"Recommendations on screening for chloroquine and hydroxychloroquine Retinopathy (2016 revision)","volume":"123","author":"Marmor","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajog.2025.09.002_bib78","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00296-003-0309-0","article-title":"Differential diagnosis of high serum creatine kinase levels in systemic lupus erythematosus","volume":"23","author":"Richter","year":"2003","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ajog.2025.09.002_bib79","doi-asserted-by":"crossref","first-page":"E194","DOI":"10.1002\/ajh.25862","article-title":"Glucose-6-phosphate dehydrogenase deficiency-associated hemolysis and methemoglobinemia in a COVID-19 patient treated with chloroquine","volume":"95","author":"Kuipers","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ajog.2025.09.002_bib80","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/rheumatology\/35.2.133","article-title":"Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies","volume":"35","author":"Ruiz-Irastorza","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib81","doi-asserted-by":"crossref","first-page":"153","DOI":"10.7326\/M14-2235","article-title":"Predictors of pregnancy outcomes in patients with lupus: a cohort study","volume":"163","author":"Buyon","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajog.2025.09.002_bib82","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/annrheumdis-2016-209770","article-title":"EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and\/or antiphospholipid syndrome","volume":"76","author":"Andreoli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajog.2025.09.002_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(25)00076-1","article-title":"Exposure to hydroxychloroquine in early pregnancy and incidence of pre-eclampsia and pre-term delivery in patients with systemic lupus erythematosus in Sweden: a nationwide population-based cohort study","author":"Nguyen","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib84","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/art.42793","article-title":"Hydroxychloroquine in lupus pregnancy and risk of preeclampsia","volume":"76","author":"Rector","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001239","article-title":"Effect of hydroxychloroquine on pregnancy outcome in patients with SLE: a systematic review and meta-analysis","volume":"11","author":"Zhu","year":"2024","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ajog.2025.09.002_bib86","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1007\/s10067-022-06496-2","article-title":"Hydroxychloroquine significantly decreases the risk of preeclampsia in pregnant women with autoimmune disorders: a systematic review and meta-analysis","volume":"42","author":"Liu","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib87","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1177\/09612033211007199","article-title":"Hydroxychloroquine prophylaxis for preeclampsia, hypertension and prematurity in pregnant patients with systemic lupus erythematosus: a meta-analysis","volume":"30","author":"Duan","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.ajog.2025.09.002_bib88","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00404-020-05762-5","article-title":"Effect of hydroxychloroquine on preeclampsia in lupus pregnancies: a propensity score-matched analysis and meta-analysis","volume":"303","author":"Liu","year":"2021","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ajog.2025.09.002_bib89","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jbspin.2018.03.006","article-title":"Hydroxychloroquine for the prevention of fetal growth restriction and prematurity in lupus pregnancy: a systematic review and meta-analysis","volume":"85","author":"Guillotin","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.ajog.2025.09.002_bib90","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/acr.25386","article-title":"Hydroxychloroquine and pre-eclampsia in a diverse cohort of women with systemic lupus erythematosus","volume":"76","author":"Simard","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ajog.2025.09.002_bib91","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/jcm12020485","article-title":"Effect of hydroxychloroquine on lupus activity, preeclampsia and intrauterine growth restriction in pregnant women with systemic lupus erythematosus and\/or antiphospholipid syndrome: a systematic review and meta-analysis","volume":"12","author":"Hu","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ajog.2025.09.002_bib92","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.preghy.2022.11.006","article-title":"Preeclampsia in women with lupus - influence of aspirin and hydroxychloroquine on pregnancy outcome","volume":"31","author":"Phillips","year":"2023","journal-title":"Pregnancy Hypertens"},{"key":"10.1016\/j.ajog.2025.09.002_bib93","doi-asserted-by":"crossref","first-page":"362","DOI":"10.31486\/toj.20.0013","article-title":"Systemic lupus erythematosus: perinatal outcomes in patients treated with and without hydroxychloroquine","volume":"20","author":"Baalbaki","year":"2020","journal-title":"Ochsner J"},{"key":"10.1016\/j.ajog.2025.09.002_bib94","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/25785826.2020.1868652","article-title":"Low incidence of intrauterine growth restriction in pregnant patients with systemic lupus erythematosus taking hydroxychloroquine","volume":"44","author":"Canti","year":"2021","journal-title":"Immunol Med"},{"key":"10.1016\/j.ajog.2025.09.002_bib95","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1055\/s-0040-1715140","article-title":"New benefits of hydroxychloroquine in pregnant women with systemic lupus erythematosus: a retrospective study in a tertiary centre","volume":"42","author":"Abd Rahman","year":"2020","journal-title":"Rev Bras Ginecol Obstet"},{"key":"10.1016\/j.ajog.2025.09.002_bib96","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1055\/s-0039-3402752","article-title":"Does hydroxychloroquine protect against preeclampsia and preterm delivery in systemic lupus erythematosus pregnancies?","volume":"37","author":"Do","year":"2020","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib97","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/0961203319843343","article-title":"Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia","volume":"28","author":"Seo","year":"2019","journal-title":"Lupus"},{"key":"10.1016\/j.ajog.2025.09.002_bib98","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/jog.14561","article-title":"Impact of hydroxychloroquine on the gestational outcomes of pregnant women with immune system problems that necessitate the use of the drug","volume":"47","author":"Beksac","year":"2021","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1016\/j.ajog.2025.09.002_bib99","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/0961203314555352","article-title":"Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus","volume":"24","author":"Koh","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.ajog.2025.09.002_bib100","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1177\/0961203310378669","article-title":"Pregnancy outcome in 396 pregnancies in patients with SLE in Saudi Arabia","volume":"19","author":"Al Arfaj","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.ajog.2025.09.002_bib101","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/0961203314551812","article-title":"Renal biopsy in the management of lupus nephritis during pregnancy","volume":"24","author":"Chen","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.ajog.2025.09.002_bib102","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.rdc.2007.02.005","article-title":"Neonatal lupus syndromes","volume":"33","author":"Izmirly","year":"2007","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.ajog.2025.09.002_bib103","doi-asserted-by":"crossref","first-page":"30444","DOI":"10.1074\/jbc.M111.263657","article-title":"A novel role of endothelin-1 in linking Toll-like receptor 7-mediated inflammation to fibrosis in congenital heart block","volume":"286","author":"Alvarez","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajog.2025.09.002_bib104","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/CRD.0000000000000026","article-title":"Prevention and treatment in utero of autoimmune-associated congenital heart block","volume":"22","author":"Saxena","year":"2014","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.ajog.2025.09.002_bib105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1161\/CIRCULATIONAHA.111.089268","article-title":"Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA\/Ro-antibody-associated cardiac manifestations of neonatal lupus","volume":"126","author":"Izmirly","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ajog.2025.09.002_bib106","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2009.119263","article-title":"Evaluation of the risk of anti-SSA\/Ro-SSB\/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine","volume":"69","author":"Izmirly","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ajog.2025.09.002_bib107","doi-asserted-by":"crossref","first-page":"64.e1-7","DOI":"10.1016\/j.ajog.2012.09.020","article-title":"Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents","volume":"208","author":"Tunks","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2025.09.002_bib108","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s12026-016-8888-5","article-title":"Obstetric and perinatal outcome in anti-Ro\/SSA-positive pregnant women: a prospective cohort study","volume":"65","author":"Mart\u00ednez-S\u00e1nchez","year":"2017","journal-title":"Immunol Res"},{"key":"10.1016\/j.ajog.2025.09.002_bib109","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1093\/rheumatology\/kex191","article-title":"Prenatal exposure to antimalarials decreases the risk of cardiac but not non-cardiac neonatal lupus: a single-centre cohort study","volume":"56","author":"Barsalou","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ajog.2025.09.002_bib110","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s10067-019-04556-8","article-title":"Causes of fetal third-degree atrioventricular block and use of hydroxychloroquine in pregnant women with Ro\/La antibodies","volume":"38","author":"Mollerach","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib111","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jacc.2020.05.045","article-title":"Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of anti-SSA\/Ro-positive mothers","volume":"76","author":"Izmirly","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ajog.2025.09.002_bib112","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/09612033211066455","article-title":"Prenatal predisposing factors associated with neonatal lupus erythematosus","volume":"31","author":"Anuwutnavin","year":"2022","journal-title":"Lupus"},{"key":"10.1016\/j.ajog.2025.09.002_bib113","first-page":"685","article-title":"Anti-SSA\/Ro positivity and congenital heart block: obstetric and foetal outcome in a cohort of anti-SSA\/Ro positive pregnant patients with and without autoimmune diseases","volume":"41","author":"Fredi","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib114","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.autrev.2007.11.011","article-title":"Lessons from the \"Euro-Phospholipid\" project","volume":"7","author":"Cervera","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ajog.2025.09.002_bib115","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s40744-020-00273-w","article-title":"Antiphospholipid antibodies in inflammatory and autoimmune rheumatic and musculoskeletal diseases beyond lupus: a systematic review of the available evidence","volume":"8","author":"El Hasbani","year":"2021","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.ajog.2025.09.002_bib116","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3390\/ijms20040892","article-title":"The impact of autoantibodies on IVF treatment and outcome: a systematic review","volume":"20","author":"Simopoulou","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ajog.2025.09.002_bib117","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1472-6483(10)62013-5","article-title":"Antiphospholipid antibodies and coagulation defects in women with implantation failure after IVF and recurrent miscarriage","volume":"13","author":"Stern","year":"2006","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.ajog.2025.09.002_bib118","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJM199707173370303","article-title":"Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism","volume":"337","author":"Rand","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajog.2025.09.002_bib119","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3390\/jcm11030675","article-title":"Pathogenesis, diagnosis and management of obstetric antiphospholipid syndrome: a comprehensive review","volume":"11","author":"Alijotas-Reig","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ajog.2025.09.002_bib120","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1177\/0961203310361485","article-title":"The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis","volume":"19","author":"Rand","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.ajog.2025.09.002_bib121","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/jth.12570","article-title":"Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies","volume":"12","author":"Marchetti","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ajog.2025.09.002_bib122","doi-asserted-by":"crossref","first-page":"576.e7","DOI":"10.1016\/j.ajog.2011.06.064","article-title":"Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression","volume":"205","author":"Wu","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2025.09.002_bib123","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1160\/th15-06-0491","article-title":"The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment","volume":"115","author":"Sciascia","year":"2016","journal-title":"Thromb Haemost"},{"issue":"Suppl 1","key":"10.1016\/j.ajog.2025.09.002_bib124","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000785","article-title":"Antiphospholipid syndrome: state of the art on clinical practice guidelines","volume":"4","author":"Limper","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.ajog.2025.09.002_bib125","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.autrev.2015.01.012","article-title":"The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study","volume":"14","author":"Mekinian","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ajog.2025.09.002_bib126","doi-asserted-by":"crossref","first-page":"273.e1","DOI":"10.1016\/j.ajog.2015.09.078","article-title":"The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies","volume":"214","author":"Sciascia","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2025.09.002_bib127","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.4103\/0366-6999.207471","article-title":"Efficacy of different treatment regimens for antiphospholipid syndrome-related recurrent spontaneous abortion","volume":"130","author":"Ye","year":"2017","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ajog.2025.09.002_bib128","first-page":"639","article-title":"Effect of additional treatments combined with conventional therapies in pregnant patients with high-risk antiphospholipid syndrome: a multicentre study","volume":"118","author":"Ruffatti","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.ajog.2025.09.002_bib129","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.thromres.2021.08.004","article-title":"The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome","volume":"206","author":"Gerde","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.ajog.2025.09.002_bib130","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.autrev.2018.05.012","article-title":"HIBISCUS: hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome","volume":"17","author":"Belizna","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ajog.2025.09.002_bib131","first-page":"598","article-title":"[Hydroxychloroquine to obtain pregnancy without adverse obstetrical events in primary antiphospholipid syndrome: French phase II multicenter randomized trial, HYDROSAPL]","volume":"46","author":"Mekinian","year":"2018","journal-title":"Gynecol Obstet Fertil Senol"},{"key":"10.1016\/j.ajog.2025.09.002_bib132","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1055\/s-0037-1603359","volume":"43","author":"Schreiber","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ajog.2025.09.002_bib133","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1097\/01.AOG.0000423816.39542.0f","article-title":"Practice bulletin No. 132: antiphospholipid syndrome","volume":"120","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2025.09.002_bib134","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/acr.25422","article-title":"Therapeutic hydroxychloroquine blood levels are associated with fewer hospitalizations and possible reduction of health disparities in lupus","volume":"76","author":"Garg","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ajog.2025.09.002_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111269","article-title":"The presumable effects of hydroxychloroquine and its metabolites in the treatment of systemic lupus erythematosus","volume":"126","author":"Pan","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ajog.2025.09.002_bib136","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000841","article-title":"Hydroxychloroquine daily dose, hydroxychloroquine blood levels and the risk of flares in patients with systemic lupus erythematosus","volume":"10","author":"Fasano","year":"2023","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ajog.2025.09.002_bib137","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1146\/annurev-pharmtox-011613-140009","article-title":"Pharmacometrics in pregnancy: an unmet need","volume":"54","author":"Ke","year":"2014","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.ajog.2025.09.002_bib138","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3899\/jrheum.180158","article-title":"Hydroxychloroquine levels throughout pregnancies complicated by rheumatic disease: implications for maternal and neonatal outcomes","volume":"46","author":"Balevic","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ajog.2025.09.002_bib139","series-title":"Optimal hydroxychloroquine drug levels in pregnant women with systemic lupus erythematosus","author":"Balevic","year":"2019"},{"key":"10.1016\/j.ajog.2025.09.002_bib140","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40262-018-0712-z","article-title":"Pharmacokinetics of hydroxychloroquine in pregnancies with rheumatic diseases","volume":"58","author":"Balevic","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ajog.2025.09.002_bib141","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000602","article-title":"Hydroxychloroquine PK and exposure-response in pregnancies with lupus: the importance of adherence for neonatal outcomes","volume":"9","author":"Balevic","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ajog.2025.09.002_bib142","article-title":"Hydroxychloroquine levels in pregnancy and materno-fetal outcomes in Systemic Lupus Erythematosus patients","author":"Alle","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ajog.2025.09.002_bib143","doi-asserted-by":"crossref","first-page":"i55","DOI":"10.1093\/rheumatology\/keu095.004","article-title":"Longterm outcomes of children born to mothers with SLE exposed to hydroxychloroquine in pregnancy","volume":"53","author":"Gayed","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.ajog.2025.09.002_bib144","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00228-019-02723-z","article-title":"Breast milk concentration of hydroxychloroquine in Chinese lactating women with connective tissue diseases","volume":"75","author":"Peng","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ajog.2025.09.002_bib145","first-page":"E261","volume":"36","author":"Liu","year":"2016","journal-title":"Excretion of hydroxychloroquine in milk of lactating patients. Pharmacotherapy"},{"key":"10.1016\/j.ajog.2025.09.002_bib146","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00296-019-04372-y","article-title":"Kuwait association of rheumatology 2018 treatment recommendations for patients with rheumatoid arthritis","volume":"39","author":"Alhajeri","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ajog.2025.09.002_bib147","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.reuma.2019.04.002","article-title":"Update of the Mexican College of rheumatology guidelines for the pharmacological treatment of rheumatoid arthritis, 2018","volume":"17","author":"Cardiel","year":"2021","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"10.1016\/j.ajog.2025.09.002_bib148","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1542\/peds.108.3.776","article-title":"AoPCo. Transfer of drugs and other chemicals into human milk","volume":"108","year":"2001","journal-title":"Pediatrics"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937825006532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937825006532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T20:24:42Z","timestamp":1787948682000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937825006532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":148,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0002937825006532"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2025.09.002","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hydroxychloroquine in systemic lupus erythematosus, anti-SSA\/SSB, and antiphospholipid antibody-positive pregnancies","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2025.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}